Status:
COMPLETED
Chemerin, Fetuin-A, IL-34 and IL-13 Levels in Diabetic Periodontitis Patients
Lead Sponsor:
Marmara University
Conditions:
Periodontitis
Diabetes Mellitus, Type 2
Eligibility:
All Genders
23-69 years
Phase:
NA
Brief Summary
The present study aimed to assess the effect of non-surgical periodontal treatment on serum and salivary chemerin, fetuin-A, IL-34 and IL-13 levels in periodontitis with and without diabetes mellitus ...
Detailed Description
Type 2 diabetes (T2DM) increases the risk for severe periodontal disease by three times, making it a risk factor for the progression of periodontitis. Periodontitis works as a focus of local infection...
Eligibility Criteria
Inclusion
- non-smoker individuals
- having ≥20 teeth present (except third molars)
- individuals with non-periodontitis (healthy or gingivitis) and stage III grade C periodontitis diagnoses
- diagnosed at least one year ago as having T2DM and treated with oral anti-diabetics and/or insulin, no major diabetic complications (retinopathy, nephropathy, neuropathy)
Exclusion
- having any diagnosed medical disorders other than diabetes mellitus, such as cardiovascular diseases, rheumatoid arthritis, immunological and mucocutaneous diseases
- usage of antibiotics, non-steroidal anti-inflammatory drugs, and immunosuppressive agents within the past 6 months.
- periodontal treatment within the preceding 6 months.
- pregnant/ lactating/ postmenopausal females.
- current orthodontic treatment.
Key Trial Info
Start Date :
October 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 21 2020
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT06135532
Start Date
October 1 2018
End Date
February 21 2020
Last Update
November 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Marmara University
Istanbul, Turkey (Türkiye), 34854